QuidelOrtho Corp
QDEL29.530USD
+0.610+2.11%
Close 09/16, 16:00（ET）Quotes delayed by 15 min
2.00BMarket Cap
LossP/E TTM
More Details of QuidelOrtho Corp Company
QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories.
Company Info
Ticker SymbolQDEL
Company nameQuidelOrtho Corp
IPO dateFeb 01, 1991
CEOMr. Brian J. Blaser
Number of employees6600
Security typeOrdinary Share
Fiscal year-endFeb 01
Address9975 Summers Ridge Road
CitySAN DIEGO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92121
Phone18585521100
Websitehttps://www.quidelortho.com/
Ticker SymbolQDEL
IPO dateFeb 01, 1991
CEOMr. Brian J. Blaser
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
104.41K
+9.68%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
72.55K
+7.29%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
33.58K
+75.18%
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
29.21K
+25.00%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
21.35K
+35.98%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
14.27K
+75.49%
Mr. Brian J. Blaser
Mr. Brian J. Blaser
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.45K
--
Mr. John R. Chiminski
Mr. John R. Chiminski
Independent Director
Independent Director
2.52K
--
Sergio Gadaleta
Sergio Gadaleta
Senior Vice President - Clinical and Regulatory Affairs
Senior Vice President - Clinical and Regulatory Affairs
--
--
Devon Burek
Devon Burek
Senior Vice President - Global Quality
Senior Vice President - Global Quality
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
104.41K
+9.68%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
72.55K
+7.29%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
33.58K
+75.18%
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
29.21K
+25.00%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
21.35K
+35.98%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
14.27K
+75.49%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Labs
373.10M
53.85%
Point-of-Care
170.80M
24.65%
Immunohematology
128.50M
18.55%
Donor Screening
12.80M
1.85%
Molecular Diagnostic Solutions
7.60M
1.10%
By RegionUSD
Name
Revenue
Proportion
North America
406.70M
58.70%
Other
122.20M
17.64%
EMEA
88.90M
12.83%
China
75.00M
10.83%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Labs
373.10M
53.85%
Point-of-Care
170.80M
24.65%
Immunohematology
128.50M
18.55%
Donor Screening
12.80M
1.85%
Molecular Diagnostic Solutions
7.60M
1.10%
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
16.40%
BlackRock Institutional Trust Company, N.A.
13.67%
The Vanguard Group, Inc.
11.44%
Rubric Capital Management LP
6.83%
State Street Global Advisors (US)
3.98%
Other
47.69%
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
16.40%
BlackRock Institutional Trust Company, N.A.
13.67%
The Vanguard Group, Inc.
11.44%
Rubric Capital Management LP
6.83%
State Street Global Advisors (US)
3.98%
Other
47.69%
Shareholder Types
Shareholders
Proportion
Investment Advisor
66.33%
Investment Advisor/Hedge Fund
32.08%
Hedge Fund
14.79%
Research Firm
2.12%
Pension Fund
1.25%
Individual Investor
0.92%
Private Equity
0.69%
Bank and Trust
0.65%
Sovereign Wealth Fund
0.52%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
684
78.51M
115.63%
-21.42M
2025Q1
726
76.59M
113.26%
-21.60M
2024Q4
747
75.07M
111.30%
-13.02M
2024Q3
744
73.58M
109.44%
-4.02M
2024Q2
767
70.18M
104.79%
-7.57M
2024Q1
799
67.05M
100.24%
-5.28M
2023Q4
828
68.21M
102.09%
-2.95M
2023Q3
842
70.19M
105.17%
-4.01M
2023Q2
860
68.99M
103.61%
-6.94M
2023Q1
894
68.68M
103.29%
-6.80M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
T. Rowe Price Investment Management, Inc.
11.45M
16.93%
+208.36K
+1.85%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.55M
11.17%
-233.81K
-3.00%
Mar 31, 2025
The Vanguard Group, Inc.
6.72M
9.94%
-77.05K
-1.13%
Mar 31, 2025
Rubric Capital Management LP
6.14M
9.08%
+590.00K
+10.63%
Mar 31, 2025
State Street Global Advisors (US)
2.19M
3.24%
-83.38K
-3.67%
Mar 31, 2025
Fidelity Management & Research Company LLC
1.26M
1.86%
+7.91K
+0.63%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.82M
2.69%
+600.34K
+49.32%
Mar 31, 2025
D. E. Shaw & Co., L.P.
1.34M
1.99%
-385.59K
-22.31%
Mar 31, 2025
American Century Investment Management, Inc.
1.59M
2.35%
+473.09K
+42.41%
Mar 31, 2025
AQR Capital Management, LLC
2.66M
3.93%
+1.85M
+230.30%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
SPDR S&P Health Care Equipment ETF
1.76%
Invesco S&P SmallCap Health Care ETF
1.43%
SPDR S&P 600 Small Cap Value ETF
0.29%
iShares S&P Small-Cap 600 Value ETF
0.29%
Avantis US Small Cap Value ETF
0.23%
iShares U.S. Medical Devices ETF
0.22%
VictoryShares US Small Mid Cap Value Momentum ETF
0.18%
Invesco S&P SmallCap 600 Revenue ETF
0.18%
Avantis US Small Cap Equity ETF
0.17%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
0.16%
View more
SPDR S&P Health Care Equipment ETF
Proportion1.76%
Invesco S&P SmallCap Health Care ETF
Proportion1.43%
SPDR S&P 600 Small Cap Value ETF
Proportion0.29%
iShares S&P Small-Cap 600 Value ETF
Proportion0.29%
Avantis US Small Cap Value ETF
Proportion0.23%
iShares U.S. Medical Devices ETF
Proportion0.22%
VictoryShares US Small Mid Cap Value Momentum ETF
Proportion0.18%
Invesco S&P SmallCap 600 Revenue ETF
Proportion0.18%
Avantis US Small Cap Equity ETF
Proportion0.17%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
Proportion0.16%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
